PRMT5 restricts ERK activity

被引：0
|
作者：
Katharine H. Wrighton
机构：
来源：
Nature Reviews Molecular Cell Biology | 2011年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
PRMT5 methylates RAF proteins to decrease their stability and reduce ERK activation.
引用
收藏
页码：689 / 689
相关论文
共 50 条
  • [31] PRMT5 inhibitors as novel treatment for cancers
    Falk, Hendrik
    Foitzik, Richard C.
    Allan, Elizabeth
    deSilva, Melanie
    Yang, Hong
    Bozikis, Ylva E.
    Nikac, Marica
    Walker, Scott R.
    Camerino, Michelle A.
    Morrow, Ben J.
    Stupple, Alexandra E.
    Lagiakos, Rachel
    Pinson, Jo-Anne
    Lessene, Romina
    Kersten, Wilhelmus J. A.
    Ganame, Danny G.
    Holmes, Ian P.
    Lunniss, Gill E.
    Chung, Matthew
    Hermans, Stefan J.
    Parker, Michael W.
    Thistlethwaite, Alison
    White, Karen
    Charman, Susan A.
    Monahan, Brendon J.
    Pilling, Patricia
    Grusovin, Julian
    Peat, Thomas S.
    Sonderegger, Stefan
    Toulmin, Emma
    Jane, Stephen M.
    Curtis, David J.
    Stupple, Paul A.
    Street, Ian P.
    CANCER RESEARCH, 2015, 75
  • [32] Acetylation regulates the oncogenic functions of PRMT5
    Vo, Tam Thuy Lu
    Do, Yen Thi
    Pham, Thi Tuyet Mai
    Shin, So-Jin
    Kim, Jin Young
    Lee, Seungmee
    Ha, Eunyoung
    Seo, Ji Hae
    CANCER RESEARCH, 2023, 83 (07)
  • [33] PRMT5 AS A DRUGGABLE TARGET FOR GLIOBLASTOMA THERAPY
    Banasavadi-Siddegowda, Yeshavanth Kumar
    Welker, Alessandra M.
    Imitola, Jaime
    Li, Chenglong
    Zhang, Jianying
    Beattie, Christine E.
    Baiocchi, Robert
    Kaur, Balveen
    NEURO-ONCOLOGY, 2017, 19 : 78 - 78
  • [34] Medicinal chemistry insights into PRMT5 inhibitors
    Jiao, Zhihao
    Huang, Yongmi
    Gong, Kexin
    Liu, Yiru
    Sun, Jinxiao
    Yu, Shangzhe
    Zhao, Guisen
    BIOORGANIC CHEMISTRY, 2024, 153
  • [35] PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
    Welliver, Meng
    Jin, Feng
    Otterson, Gregory
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S844
  • [36] Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors
    Lin, Hong
    Luengo, Juan, I
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (11) : 1264 - 1269
  • [37] Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)
    Palte, Rachel L.
    Schneider, Sebastian E.
    Altman, Michael D.
    Hayes, Robert P.
    Kawamura, Shuhei
    Lacey, Brian M.
    Mansueto, My Sam
    Reutershan, Michael
    Siliphaivanh, Phieng
    Sondey, Christopher
    Xu, Haiyan
    Xu, Zangwei
    Ye, Yingchun
    Machacek, Michelle R.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (09): : 1688 - 1693
  • [38] Study on biological activity of various truncations of human PRMT5 in E. coli
    Sun Li-Tao
    Zhou Zhong-Wei
    Xie Xiao-Dong
    Bao Shi-Lai
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2008, 35 (07) : 801 - 806
  • [39] PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer
    Huang, Jianhao
    Zheng, Yonghua
    Zheng, Xiao
    Qian, Bao
    Yin, Qi
    Lu, Jingjing
    Lei, Han
    CELL TRANSPLANTATION, 2021, 30
  • [40] The role of PRMT5 in MYC-driven medulloblastoma
    Chaturvedi, Nagendra K.
    Kesherwani, Varun
    Kling, Matthew J.
    Ray, Sutapa
    McGuire, Timothy R.
    Joshi, Shantaram S.
    Sharp, J. Graham
    Coulter, Don W.
    CANCER RESEARCH, 2019, 79 (13)
12345